Quanterix Advances Alzheimer’s Strategy Amidst 25% Revenue Growth and FDA Filing

Quanterix’s fourth-quarter 2025 performance highlights a pivotal transition for the company as it shifts from a research-focused life sciences tools provider to a clinical diagnostics powerhouse. Total revenue reached $43.9 million, a 25% increase year-over-year, though this figure was heavily influenced by the integration of Akoya. On an organic basis, the company faced a 22% decline, reflecting a challenging environment for large-scale pharmaceutical projects and academic spending. However, the underlying strategic narrative is dominated by the company’s aggressive expansion into the Alzheimer’s disease (AD) diagnostic market, where it is positioning its Simoa technology as the gold standard for high-sensitivity blood-based biomarkers.

The most significant development in the quarter was the progress of the Lucent AD Complete test. Quanterix secured a national reference price of $897 from the Centers for Medicare & Medicaid Services (CMS), a critical milestone for commercial viability. This reimbursement rate provides a clear path for clinical adoption, as it removes one of the primary barriers for healthcare providers and patients seeking accessible AD testing. Furthermore, the company’s January 2026 submission of a 510(k) premarket notification to the FDA signals that Quanterix is entering the final stages of regulatory validation for its clinical diagnostic portfolio. This move is timed to coincide with the broader industry shift toward blood-based testing, which is increasingly seen as a more scalable and less invasive alternative to PET scans and cerebrospinal fluid (CSF) analysis.

“

Simoa revenue stood at $27 million, representing a 22% organic decline, while Spatial revenue fell 23% to $17 million.

Despite the regulatory momentum, the company’s core research business faced headwinds. Simoa revenue stood at $27 million, representing a 22% organic decline, while Spatial revenue fell 23% to $17 million. This downturn was largely attributed to a reduction in large-scale Accelerator projects from pharmaceutical partners, which decreased by 21%. The academic sector, which accounts for 55% of Quanterix’s business, also showed signs of budget tightening, with a pro forma revenue decline of 24%. These figures suggest that while the long-term clinical opportunity is expanding, the short-term research market remains volatile as biopharma companies recalibrate their R&D spending in a high-interest-rate environment.